Table 2.

Vacuolar pH (A) and area (B) experimental measurements and statistics for potassium channel inhibitors.

(A) Vacuolar SNARF ratio
N	Control	No. of points	Control median (SFR/pH)		Inhibitor	No. of points	Inhibitor median (SFR/pH)		p-value
3	Control	271	2.1	9.1	Anandamide	230	1.8	8.9	1.64 × 10-5
4	Control	342	1.9	8.9	Quinidine	348	2.0	9.1	0.264
3	Zinc	308	2.2	9.2	Anandamide + zinc	128	1.9	9.0	1.12 × 10-6
4	Zinc	372	2.2	9.2	Quinidine + zinc	461	2.1	9.1	3.88 × 10-6
(B) Vacuolar area
N	Control	No. of points	Control median (±SD)		Inhibitor	No. of points	Inhibitor median (±SD)		p-value
3	Control	336	12.8 (3.5)		Anandamide	346	12.8(3.6)		0.085
4	Control	374	13.2 (3.9)		Quinidine	484	13.1(3.4)		0.364
3	Zinc	392	14.2 (4.0)		Anandamide + zinc	324	12.6 (2.7)		6.11 × 10-14
4	Zinc	470	13.9 (4.0)		Quinidine + zinc	522	13.2(3.2)		2.54 × 10-4

N = number of experiments performed, no. of points describes the total number of individual measurements. The control and corresponding knockout medians are accompanied with the SFR and converted vacuolar pH and standard deviation (SD) for the vacuolar area.